A shadow market for unapproved slimming drugs is being driven by social media fitness personalities and vendors on communication apps, based on recent findings.
Experimental Drug Acquiring Popularity Via Social Media
Retatrutide, which is still in research studies, is being advertised by social media influencers for its alleged weight-reducing properties. Followers are encouraged to message these profiles directly for source information, while also obtaining discount codes.
Thriving Commerce on Messaging Platforms
Separately, a flourishing market exists on Telegram, where groups with thousands of members share “before and after” photos, administration instructions and assertions of rapid UK delivery. Sellers promote the drug there before directing buyers to other platforms for purchases.
Understanding Retatrutide
Retatrutide is an investigational injection developed by US drugmaker Eli Lilly. The treatment targets three gut hormones – GLP-1, GIP and pancreatic hormone. Preliminary studies suggest it could assist patients lose up to a quarter of their total weight. Nicknamed the “triple G”, the substance is being promoted digitally as the successor to Ozempic.
Healthcare Professionals Voice Concerns
Nevertheless, doctors and pharmacists have cautions that the sale of what is still an unapproved drug in the United Kingdom is a cause for concern and could result in individuals administering products of uncertain source.
Several experts said the demand for the experimental drug could be linked to the increasing cost of approved weight loss treatments such as Mounjaro.
Legal Status and Enforcement
Selling retatrutide on TikTok or messaging apps is illegal in the UK, as it is an unlicensed drug that must not be marketed or supplied for human use under the British medical regulations.
Some content creators try to circumvent the regulations by referring to the drug as a “research chemical” or citing it as “not for human consumption”. The substance is not a controlled substance, but advertising and distribution can still breach medicines, advertising, and customer regulations, potentially leading to fines, prosecution or imprisonment.
Service Reaction and Content Elimination
Based on the social media company, the service has taken down problematic content and prohibited associated hashtags and search suggestions. The organization said it was committed to maintaining the service safe and investing in strengthening compliance measures.
Digital Trading Operations
Investigations also discovered communities with up to 9,000 participants marketing retatrutide using the platform's built-in discovery tool, which functions like a online catalog. Entering “retatrutide” instantly displays groups with thousands of users, populated with photos of weight loss, glowing reviews and step-by-step guides for preparing or injecting at home.
After moments of entering one group, a seller posted WhatsApp details, where the majority of purchases take place. The vendor sent an guidebook and guaranteed delivery within 48 hours. When questioned whether the substance was genuine, one seller responded: “You can’t be sure.” Another shared a photo of a alleged laboratory certificate. None asked about weight, health issues or past usage.
Product Details and Costs
Within these communities, messages show dark colored parcels with Royal Mail labels, claiming to include fresh supplies. One communication read: “It took eight of us to load them this morning.”
Customers can select between dry substance containers, mixed at home with sterile water, or ready-to-use pens usually priced at £160 for 20mg. When questioned how much time a injector should last, sellers give conflicting responses ranging from a few weeks to “depends on your body”.
Platform Oversight and Safety Actions
A representative for the messaging service said it regularly monitored harmful content on its platform including material that encouraged the “misuse of controlled medications”. The company added that it removed “millions of pieces of harmful content each day”.
Healthcare Professional Warnings
“Individuals are injecting materials they cannot confirm. Even if the research behind this drug is valid, these online products may not include what they advertise,” stated Jason Murphy, the director of pharmaceutical services at Chemist4U.
Dr Crystal Wyllie of an online medical service linked the surge in demand to recent cost increases for approved weight-loss drugs such as Mounjaro. “With prices rising, patients are turning to online platforms. But counterfeit injections are extremely risky. You cannot know what’s inside or whether the environment they were made in was clean,” she explained.
Her team has previously encountered individuals injured by self-injection from unverified sources. “We understand the disappointment, but buying from Telegram or communication platforms is gambling with your well-being,” stated Wyllie. “These materials could be contaminated or incorrectly dosed.”
Producer Position
A representative from the pharmaceutical company stated retatrutide was in phase 3 research studies and had not been evaluated or authorized by any government authority anywhere in the world. “Consequently at this time no one can market [it] for human use,” they said, noting that any product “falsely representing itself as a Lilly investigational product not yet approved … may expose users to possibly significant medical dangers”.
